Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Wei Peng, Jifeng Feng

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of B-cell lymphomas. Exploring a novel and important biomarker is indispensable for understanding the mechanism and clinical course of DLBCL. Emerging studies have shown that aberrant expression of long noncoding RNA (lncRNAs) is strongly associated with carcinogenesis. The aim of this study was to investigate the value of lncRNA LUNAR1 in DLBCL. Quantitative real-time PCR was performed to illustrate the patterns of LUNAR1 expression in tumor tissues and cell lines. The higher expression of LUNAR1 was significantly correlated with stage, rituximab and IPI. Univariate and multivariate analyses showed that LUNAR1 expression served as an independent predictor for overall survival and progression-free survival. Receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic values and the area under the ROC curve of LUNAR1 was up to 0.9420. Further experiments revealed that LUNAR1 knockdown significantly repressed cell proliferation of DLBCL by regulating E2F1, cyclin D1 and p21. In conclusion, our results indicate that LUNAR1 may serve as a candidate prognostic biomarker through growth regulation in DLBCL.

References

Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Izidore S Lossos
May 10, 2007·Journal of Cellular and Molecular Medicine·B M Pützer
Feb 26, 2009·Cell·Chris P PontingWolf Reik
May 6, 2009·Journal of Cellular Physiology·Jong Kyong Kim, J Alan Diehl
May 15, 2009·Nature Reviews. Cancer·Tarek Abbas, Anindya Dutta
Jan 5, 2011·Cancer Research·Miao-Chih TsaiHoward Y Chang
Dec 15, 2011·Current Cancer Drug Targets·L A StivalaE Prosperi
Jan 30, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Man-Tang QiuLin Xu
Sep 24, 2013·Leukemia Research·Krystyna Mazan-Mamczarz, Ronald B Gartenhaus
Nov 22, 2013·Breast Cancer Research and Treatment·Kristina P SørensenTorben A Kruse

❮ Previous
Next ❯

Citations

Oct 25, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wei Peng, Hong Fan
Oct 25, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wei Peng, Airen Jiang
Nov 11, 2017·Future Oncology·Gu SiyuWilliam C Cho
Sep 28, 2017·Oncotarget·Lucia NobiliAntonino Neri
Dec 22, 2016·Journal of Translational Medicine·Xin WangFelipe Samaniego
Jan 31, 2020·Journal of Cardiovascular Translational Research·Wenbin LuQiming Dai
Jul 14, 2017·Cancer Research·Arunoday BhanSubhrangsu S Mandal
Nov 17, 2020·Frontiers in Oncology·Jingwen LiYu Hu
Dec 3, 2020·OncoTargets and Therapy·Yan ShiShuhong Hao
Dec 18, 2020·Frontiers in Genetics·América Ramírez-ColmeneroSelene L Fernandez-Valverde
Nov 6, 2020·Journal of Experimental & Clinical Cancer Research : CR·Yalu ZhangQuan Liao
Feb 18, 2021·Experimental Hematology & Oncology·Philippe DecruyenaereJo Vandesompele
Mar 1, 2020·European Journal of Pharmacology·Soudeh Ghafouri-FardMohammad Taheri
Jul 26, 2021·Journal of Experimental & Clinical Cancer Research : CR·Krishnapriya M VarierBabu Gajendran

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.